Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRandomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
Journal of Clinical Oncology, 09/11/09
Mok TSK et al. – Sequential administration of erlotinib following gemcitabine/platinum chemotherapy led to a significant improvement in PFS.
Methods- Previously untreated patients (n = 154) with stage IIIB or IV NSCLC and ECOG PS of 0 or 1 were randomly assigned to receive erlotinib (150 mg/d) or placebo on d 15-28 of a 4-w cycle that included gemcitabine (1,250 mg/m2 d 1 and 8) and either cisplatin (75 mg/m2 d 1) or carboplatin (5 x area under the serum concentration-time curve, d 1)
- The NPR at 8 weeks was 80.3% in the gemcitabine plus cisplatin or carboplatin (GC) -erlotinib arm (n = 76) and 76.9% in the GC-placebo arm (n = 78)
- At 16 w, the NPR was 64.5% for GC-erlotinib versus 53.8% for GC-placebo
- The response rate was 35.5% for GC-erlotinib versus 24.4% for GC-placebo
- PFS was significantly longer with GC-erlotinib than with GC-placebo (adjusted HR, 0.47; median, 29.4 v 23.4 w)
- There was no significant difference in OS
- The addition of erlotinib to chemotherapy was well tolerated, with no increase in hematologic toxicity, and no treatment-related interstitial lung disease
Related Articles
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 83%
Highly concordant coexpression of aromatase and estrogen receptor beta in non–small cell lung cancer
Human Pathology, 10/08/09
Relevance Score: 83%
Pathophysiologic Correlation Between 62Cu-ATSM and 18F-FDG in Lung Cancer
The Journal of Nuclear Medicine, 11/17/09
Relevance Score: 82%
Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
Journal of Clinical Oncology, 11/12/09
Relevance Score: 82%
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801
Journal of Clinical Oncology, 10/29/09
Relevance Score: 81%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09
Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer
Clinical Cancer Research, 12/17/09
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
Clinical Cancer Research, 12/17/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4?,5-trimethoxylstilbene-3?-O-phosphate disodium (M410)
Investigational New Drugs, 12/17/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor